Imaging prostate cancer: An update on positron emission tomography and magnetic resonance imaging

被引：37

作者：

Bouchelouche K. ^{[1
]}

Turkbey B. ^{[2
]}

Choyke P. ^{[2
]}

Capala J. ^{[3
]}

机构：

[1] PET and Cyclotron Unit, University of Copenhagen, Rigshospitalet, Copenhagen 2100

[2] Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD

[3] Molecular Targeting Section, National Cancer Institute, National Institutes of Health, Bethesda, MD

来源：

Current Urology Reports | 2010年 / 11卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Diffusion-weighted MRI; Dynamic contrast-enhanced MRI; Imaging; Magnetic resonance imaging; Magnetic resonance spectroscopy; MRI; MRS; PET; PET/CT; Positron emission tomography; Prostate cancer;

D O I：

10.1007/s11934-010-0105-9

中图分类号：

学科分类号：

摘要：

Prostate cancer is a common cancer in men and continues to be a major health problem. Imaging plays an essential role in the clinical management of patients. An important goal for prostate cancer imaging is more accurate disease characterization through the synthesis of anatomic, functional, and molecular imaging information. Developments in imaging technologies, specifically magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT), have improved the detection rate of prostate cancer. MRI has improved lesion detection and local staging. Furthermore, MRI allows functional assessment with techniques such as diffusion-weighted MRI, MR spectroscopy, and dynamic contrast-enhanced MRI. The most common PET radiotracer, 18F-fluorodeoxyglucose, is not very useful in prostate cancer. However, in recent years other PET tracers have improved the accuracy of PET/CT imaging of prostate cancer. Among these, choline (labeled with 18F or 11C), 11C-acetate, and 18F-fluoride have demonstrated promising results, and other new radiopharmaceuticals are currently under evaluation in preclinical and clinical studies. © 2010 Springer Science+Business Media, LLC.

引用

页码：180 / 190

页数：10

共 62 条

[11]

Toth G., Lengyel Z., Balkay L., Salah M.A., Tron L., Toth C., Detection of prostate cancer with <sup>11</sup>C-methionine positron emission tomography, Journal of Urology, 173, 1, pp. 66-69, (2005)

[12]

Schuster D.M., Votaw J.R., Nieh P.T., Et al., Initial experience with the radiotracer anti-1-amino-3-18F- fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma, J Nucl Med, 48, pp. 56-63, (2007)

[13]

Dehdashti F., Picus J., Michalski J.M., Dence C.S., Siegel B.A., Katzenellenbogen J.A., Welch M.J., Positron tomographic assessment of androgen receptors in prostatic carcinoma, European Journal of Nuclear Medicine and Molecular Imaging, 32, 3, pp. 344-350, (2005)

[14]

Elsasser-Beile U., Buhler P., Wolf P., Targeted therapies for prostate cancer against the prostate specific membrane antigen, Curr Drug Targets, 10, pp. 118-125, (2009)

[15]

Bouchelouche K., Choyke P.L., Capala J., Prostate specific membrane antigen-a target for imaging and therapy with radionuclides, Discov Med, 9, pp. 55-61, (2010)

[16]

Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S., Goldsmith S.J., Bander N.H., Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer, Journal of Clinical Oncology, 22, 13, pp. 2522-2531, (2004)

[17]

Bander N.H., Milowsky M.I., Nanus D.M., Kostakoglu L., Vallabhajosula S., Goldsmith S.J., Phase I trial of <sup>177</sup>Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer, Journal of Clinical Oncology, 23, 21, pp. 4591-4601, (2005)

[18]

Bander N.H., Wolf P., Freudenberg N., Buhler N., Et al., Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer, Prostate, 70, pp. 562-569, (2010)

[19]

Regino C.A., Wong K.J., Milenic D.E., Et al., Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen, Curr Radiopharm, 2, pp. 9-17, (2009)

[20]

Elsasser-Beile U., Reischl G., Wiehr S., Et al., PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen, J Nucl Med, 50, pp. 606-611, (2009)

← 1 2 3 4 5 6 7 →